New York, NY -- (SBWIRE) -- 12/05/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Oracle Corporation (NYSE:ORCL), Dendreon Corporation (NASDAQ:DNDN), Zalicus Inc (NASDAQ:ZLCS), LUKOIL (ADR) (OTCMKTS:LUKOY)
Oracle Corporation (NYSE:ORCL) showed a volume of 20.00 million shares by the end of last trade whereas the average volume of the stock remained 17.19million shares. The stock opened the session at $34.90 but then moved to $35.07. Oracle Corporation is a provider of enterprise software and computer hardware products and services. The Company's software, hardware systems, and services businesses develops, manufactures, markets, hosts and supports database and middleware software, applications software, and hardware systems, with the latter consisting primarily of computer server and storage products.
Is ORCL a Solid Investment at These Levels? Read This Report For Details
Dendreon Corporation (NASDAQ:DNDN) opened the session at $2.96 and closed the session at $3.05. The stock showed a positive performance of 2.69% in previous trading session. Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may significantly improve cancer treatment options for patients. The Company's product portfolio includes active cellular immunotherapies and a small molecule product candidate that could be applicable to treating multiple types of cancers. PROVENGE (sipuleucel-T),
For How Long DNDN will fight for Profitability? Read This Trend Analysis report
Zalicus Inc (NASDAQ:ZLCS) opened the session at $1.11 and closed the session at $1.21. The stock showed a positive performance of 6.14% in previous trading session. The beta of the stock remained 1.70. Zalicus Inc. (Zalicus) is a biopharmaceutical company that discovers and developsl treatments for patients suffering from pain and immuno-inflammatory diseases. The Company has a portfolio of clinical-stage product candidates targeting pain and immuno-inflammatory diseases and have entered into multiple revenue-generating collaborations with large pharmaceutical companies relating to other products,
Why Should Investors Buy ZLCS After The Recent Gain? Just Go Here and Find Out
LUKOIL (ADR) (OTCMKTS:LUKOY) the stock advanced 0.27% and finished the session at $60.43. Traded with volume of 84,704.00 shares in the prior session and the average volume of the stock remained 93,111.00 shares. The beta of the stock remained 1.19. NK Lukoil OAO (Neftyanaya Kompaniya LUKOIL OAO or NK LUKOIL OJSC) is a Russia-based integrated oil and gas company. The Company is engaged in the business of oil exploration, production, refining, marketing and distribution. It is an owner of refineries, gas processing, petrochemical plants and gas stations network located in Russia, Eastern and Western Europe, as well as Africa. The Company’s petroleum products are sold in the Russian Federation, the Commonwealth of Independent States (CIS) countries, Eastern and Western Europe, Asia and the United States.
Will LUKOY Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)